Ex-exec: Off-label promo 'part of Pfizer culture'

The ex-Pfizer sales manager sentenced for off-label promotion of the Bextra painkiller told Massachusetts officials that the company not only knew about her off-label activities, but encouraged them. According to a sentencing memo filed in federal district court (and obtained by BNet Pharma), off-label promotion of Bextra was "part of the Pfizer culture."

As you know, Pfizer agreed to pay $2.3 billion to settle off-label Bextra marketing claims. Mary Holloway's sentencing memo claims that she took the initiative to commission research on Bextra-type drugs for post-op pain relief, and Pfizer not only trumpeted the study results, but complimented her efforts to push Bextra for related off-label uses. The memo also details the company's alleged efforts to promote treatment protocols--which included off-label use of Bextra--to doctors. The protocol effort encompassed multiple Pfizer sales regions, the memo states.

Of course it's to Holloway's benefit to paint her own off-label marketing as just one part of an overall company effort. But Pfizer did settle with the feds for a whopping $2.3 billion--and this after the media went ga-ga over Eli Lilly's record-breaking $1.4 billion deal on off-label Zyprexa promotions.

- read the BNet Pharma item
- check out the sentencing memo


Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.